Kevin Feeley Sells 6,187 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 6,187 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total value of $486,360.07. Following the transaction, the chief financial officer owned 18,674 shares in the company, valued at $1,467,963.14. This represents a 24.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Thursday, January 29th, Kevin Feeley sold 317 shares of GeneDx stock. The stock was sold at an average price of $93.99, for a total transaction of $29,794.83.
• On Tuesday, December 16th, Kevin Feeley sold 3,855 shares of GeneDx stock. The shares were sold at an average price of $143.87, for a total transaction of $554,618.85.
• On Tuesday, December 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The shares were sold at an average price of $159.28, for a total transaction of $201,648.48.

GeneDx Stock Up 7.5%

NASDAQ:WGS opened at $88.11 on Friday. GeneDx Holdings Corp. has a 52 week low of $55.17 and a 52 week high of $170.87. The stock’s fifty day moving average is $100.80 and its two-hundred day moving average is $122.16. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of -117.48 and a beta of 2.03. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. The business had revenue of $120.99 million for the quarter, compared to analysts’ expectations of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. Research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the company. BTIG Research lowered their target price on GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a report on Tuesday, February 24th. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Wells Fargo & Company raised shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price objective on the stock in a research note on Monday, February 9th. Zacks Research upgraded shares of GeneDx from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 25th. Finally, Piper Sandler restated an “overweight” rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $150.71.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Westfield Capital Management Co. LP boosted its holdings in GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after acquiring an additional 474,167 shares during the period. ARK Investment Management LLC purchased a new stake in shares of GeneDx during the third quarter valued at approximately $48,157,000. Franklin Resources Inc. lifted its position in shares of GeneDx by 60.4% during the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after purchasing an additional 411,607 shares in the last quarter. Invesco Ltd. boosted its stake in shares of GeneDx by 59.2% in the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock valued at $102,288,000 after purchasing an additional 292,394 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new position in shares of GeneDx in the third quarter valued at $31,488,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated/institutional buy: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, a strong signal of institutional confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director buying: Director Keith A. Meister made two recent purchases (140,026 shares on Mar 5 at ~$81.19 and 29,495 shares on Mar 3 at ~$70.89), increasing his stake to over 3.2M shares — a large insider accumulation that typically signals confidence and can drive demand. SEC ownership filing — Keith A. Meister purchases
• Positive Sentiment: Recent earnings beat: GeneDx topped consensus on its most recent quarterly EPS and delivered revenue roughly in line with estimates, supporting a bullish narrative around recurring revenue and margin progress (analyst consensus remains a Moderate Buy with elevated price targets).
• Neutral Sentiment: Short-interest reading shows 0 reported short interest as of Mar 5, which appears to be a data anomaly and offers little actionable signal on immediate directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 (~$2.0M) and cut her direct stake materially. Significant insider sales can worry some investors about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 (~$486k), trimming his position by roughly 25%; this adds to mixed insider signals even though the size is smaller than the institutional buys. SEC Form 4 — CFO sale

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.